Welcome to our dedicated page for Brainsway Ltd. SEC filings (Ticker: BRSYF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Brainsway Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Brainsway Ltd.'s regulatory disclosures and financial reporting.
BrainsWay Ltd. (BWAY) furnished a Form 6-K for November 2025, providing an Investor Deck as Exhibit 99.1. The report notes that the submission is a foreign private issuer filing under the Securities Exchange Act.
The company states that this Form 6-K is incorporated by reference into its existing registration statements: a Form S-8 filed April 22, 2019 and Forms F-3 filed July 22, 2024 and April 22, 2025. The filing itself contains no financial results or transaction details beyond the inclusion of the investor presentation.
BrainsWay Ltd., an Israel-based foreign private issuer, submitted a Form 6-K for November 2025. The report furnishes Exhibit 99.1, a press release titled “BrainsWay Reports Third Quarter 2025 Financial Results and Operational Highlights.” The filing is incorporated by reference into the company’s existing Form S-8 and two Form F-3 registration statements and is signed by Chief Executive Officer Hadar Levy.
BrainsWay Ltd. furnished a Form 6-K. The filing includes an exhibit announcing a National Institutes of Health grant to a leading U.S. research team investigating accelerated Deep TMS for treatment of alcohol use disorder.
The report states this Form 6-K is incorporated by reference into the company’s Form S-8 and two Form F-3 registration statements.
BrainsWay Ltd. reported a cashless exercise of a warrant by Valor BrainsWay Holdings LLC. The warrant covered 1,500,000 American Depositary Shares at an exercise price of $9.50686 per ADS and was issued in the November 2024 private placement. At the Company’s request, the exercise was completed on a cashless basis, resulting in the issuance of 553,730 ADSs to Valor with no cash proceeds to the Company.
Brainsway Ltd. reporting persons led by Valor entities and individuals amended their Schedule 13D to disclose exercise of a warrant and updated ownership. Valor BrainsWay exercised a warrant on 10/06/2025 to purchase up to 1,500,000 ADSs at an exercise price of $9.50686 per ADS and, on a cashless basis based on the 09/30/2025 closing price, will receive 553,730 ADSs upon settlement.
The combined disclosures show the Valor group holds 5,314,950 Ordinary Shares (represented by 2,657,475 ADSs), equal to 13.7% of the class; Mr. Jonathan Shulkin and Antonio Gracias report aggregate beneficial ownership of 5,851,444 and 5,801,950 Ordinary Shares respectively, equal to 15.0% and 14.9% of the class based on 37,798,726 Ordinary Shares outstanding as of 06/30/2025. The amendment adds a joint filing agreement exhibit and states no other ADS transactions in the past 60 days aside from the warrant exercise.
The report includes condensed unaudited interim financial statements and notes for the six months ended June 30, 2025, with selected disclosures on financial instruments, investments and capital structure. The company recorded a $1,443 gain and a $69 loss on financial investments denominated in New Israeli Shekels, recognized in profit or loss per IFRS 9. It invested $5,000 in Stella Ltd. for an approximately 5% minority preferred stake measured at fair value through OCI. Share‑based payment expense totaled $552 for the six months. Subsequent strategic transactions disclosed include a $5,000 convertible loan to Neurolief with milestone tranches and an option to acquire, and a planned $2,300 equity investment for ~30% of Axis Integrated Mental Health with up to $1,000 additional milestone funding.